HIMSS14, Friday: Five things to know today

It’s over. Another whirlwind of exhibits, announcements, experiences, expertise and so much more. Here’s what you need to know.

1. There will be no more delays. Regarding ICD-10, “the system will go live on Oct. 1. Let's face it. We've delayed this several times and it's time to move on,” said Centers for Medicare & Medicaid Services (CMS) Administrator Marilynn Tavenner offered the healthcare community no relief from looming compliance dates.

2. “This coming year, we’ll spend more on healthcare than on everything else we buy combined,” said Ed Park, executive vice president and COO of athenahealth. Park spoke about what healthcare can learn from Amazon’s unprecedented efforts to offer a customer-centric shopping experience.

3. Organizations able to pull off "fast and furious" EHR implementation can save millions. Lakeland Healthcare has spent $37 million of the $60 million projected on adoption and plans to realize a total of $10 million in savings.

4. Medical University of South Carolina’s coordinated clinical decision support program is driving one single reporting structure at the enterprise level, resulting in a long list of benefits. The program includes a CDS Oversight Committee, CDS Workgroup, EHR development and operations committee and ad-hoc content expert teams.

5. HIMSS15 will be at McCormick Place in Chicago, April 12-16. See you there!

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.